NATCO announces Licensing Agreement with Gilead Sciences


Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has signed a nonexclusive
licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic
hepatitis C medicines. The medicines include sofosbuvir, ledipasvir/sofosbuvir and the investigational NS5A
inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that
combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.


This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing
countries. Under the license, Natco can set its own price for the generic products it produces, paying a
royalty on sales to Gilead to support product registrations, medical education and training, safety
monitoring and other essential business activities.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.